Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies.
Emerging infectious disease outbreaks and bioterrorism attacks warrant urgent public health and medical responses. Response plans for these events may include use of medications and vaccines for which the effects on pregnant women and fetuses are unknown. Healthcare providers must be able to discuss the benefits and risks of these interventions with their pregnant patients. Recent experiences with outbreaks of severe acute respiratory syndrome, monkeypox, and anthrax, as well as response planning for bioterrorism and pandemic influenza, illustrate the challenges of making recommendations about treatment and prophylaxis for pregnant women. Understanding the physiology of pregnancy, the factors that influence the teratogenic potential of medications and vaccines, and the infection control measures that may stop an outbreak will aid planners in making recommendations for care of pregnant women during large-scale infectious disease emergencies.
Cono
Joanne
J
Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. jcono@cdc.gov
Cragan
Janet D
JD
Jamieson
Denise J
DJ
Rasmussen
Sonja A
SA
D000014:Abnormalities, Drug-Induced; D023482:Bioterrorism; D021821:Communicable Diseases, Emerging / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D011247:Pregnancy / Q000502:physiology; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000517:prevention & control*; D014611:Vaccination; D014612:Vaccines / Q000009:adverse effects
D014612:Vaccines